Skip to content
IV Injection Allopathic

L-DOX 20 mg/10 ml iv injection

Generic: Doxorubicin Hydrochloride Liposome

Company: Beacon Pharmaceuticals PLC. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength20 mg/10 ml
PackNot listed yet

Reviewed by: not listed yet. Source: not listed yet.

Last updated September 28, 2025.

Compare

Same generic, same strength

Sorted by price per iv injection. Ask your pharmacist before you switch brands.

Doxorubicin Hydrochloride Liposome 20 mg/10 ml iv injections

Prices as listed on BestinMeds.

No price is listed for this strength yet.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Doxorubicin Hydrochloride Liposome guide

Indications

Doxorubicin Hydrochloride Liposome injection is indicated for the treatment of: Ovarian Cancer: Doxorubicin Hydrochloride Liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. AIDS-Related Kaposi’s Sarcoma: It is indicated for the treatment of AIDS-related Kaposi’s sarcoma in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy. Multiple Myeloma: For the treatment of patients with multiple myeloma in combination with Bortezomib, who have not previously received Bortezomib and have received at least one prior therapy. Also indicated for the monotherapy for patients with metastatic breast cancer, where patient is associated with increased cardiac risk with conventional Doxorubicin.

Dosage and administration

Ovarian Cancer Patients: The recommended dose is 50 mg/m2 intravenously over 60 minutes every 28 days until disease progression or unacceptable toxicity. AIDS-Related Kaposi’s Sarcoma: The recommended dose is 20 mg/m2 intravenously over 60 minutes every 21 days until disease progression or unacceptable toxicity. Multiple Myeloma: The recommended dose is 30 mg/m2 intravenously over 60 minutes on day 4 of each 21-day cycle for eight cycles or until disease progression or unacceptable toxicity. Administer it after Bortezomib on day 4 of each cycle. Dose Modification: Guidelines have been proposed since Doxorubicin Hydrochloride Liposome injection exhibits nonlinear pharmacokinetics at 50 mg/m2. Dose adjustments may thus result in non-proportional greater change in plasma concentration and exposure to the drug. Patients should be carefully monitored for toxicity. Adverse events such as Palmar Plantar Erythema (PPE), hematologic toxicities, and stomatitis may be managed by dose delays and adjustments. Subsequent to the first appearance of a Grade 2 or higher adverse event, dosing should be adjusted and or delayed as described in the following tables and should not be increased at any given time. Pediatric Use: The safety and effectiveness of Doxorubicin Hydrochloride Liposome injection in pediatric patients have not been establish

Side effects

Increased risk of getting an infection Breathlessness and looking pale Tiredness and weakness Feeling or being sick Inflammation of the lining of the mouth, throat, food pipe and stomach Soreness, redness and peeling of your hands and feet Loss of appetite Hair loss Diarrhea or constipation Pain in different parts of the body Skin changes

Precautions and warnings

Cardiomyopathy: Doxorubicin Hydrochloride can cause myocardial damage, including acute left ventricular failure. Infusion-Related Reactions: Flushing, shortness of breath, facial swelling, headache, chills, chest pain, back pain, tightness in the chest and throat, fever, tachycardia, pruritus, rash, cyanosis, syncope, bronchospasm, asthma, apnea, and hypotension. Hand-Foot Syndrome (HFS): HFS or other skin toxicity required discontinuation of Doxorubicin Hydrochloride Liposome injection in 4.2% of patients. Secondary Oral Neoplasms: Secondary oral cancers, primarily squamous cell carcinoma, have been reported from post-marketing experience in patients with long-term (more than one year) exposure to Doxorubicin Hydrochloride Liposome injection. Embryo-Fetal Toxicity: Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during and for 6 months after treatment with Doxorubicin Hydrochloride Liposome injection.

Pregnancy and lactation

Pregnancy: Based on findings in animals and its mechanism of action, Doxorubicin Hydrochloride Liposome injection can cause fetal harm when administered to a pregnant woman; avoid the use of Doxorubicin Hydrochloride Liposome injection during the 1st trimester. Lactation: It is not known whether Doxorubicin Hydrochloride Liposome injection is present in human milk. Because many drugs, including anthracyclines, are excreted in human milk and because of the potential for serious adverse reactions in breastfed infants from Doxorubicin Hydrochloride Liposome injection, discontinue breastfeeding during treatment with it. Females and Males of Reproductive Potential: Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to initiating Doxorubicin Hydrochloride Liposome injection. Contraception: Doxorubicin Hydrochloride Liposome injection can cause fetal harm when administered to a pregnant woman. Doxorubicin Hydrochloride Liposome injection may damage spermatozoa and testicular tissue, resulting in possible genetic fetal abnormalities. Infertility: In females of reproductive potential, Doxorubicin Hydrochloride Liposome injection may cause infertility and result in amenorrhea. Doxorubicin Hydrochloride Liposome injection may result in oligospermia, azoospermia, and permanent loss of fertility.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250